HighTower Advisors LLC grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 408.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 122,770 shares of the company's stock after buying an additional 98,626 shares during the period. HighTower Advisors LLC's holdings in Recursion Pharmaceuticals were worth $830,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently modified their holdings of RXRX. Prosperity Wealth Management Inc. acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $257,000. Daiwa Securities Group Inc. boosted its position in shares of Recursion Pharmaceuticals by 28.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company's stock worth $69,000 after buying an additional 2,235 shares during the period. PNC Financial Services Group Inc. boosted its position in Recursion Pharmaceuticals by 220.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock worth $66,000 after acquiring an additional 6,758 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its holdings in shares of Recursion Pharmaceuticals by 15.3% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 845,154 shares of the company's stock valued at $5,713,000 after purchasing an additional 112,221 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $609,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Stock Performance
RXRX traded down $0.55 during trading hours on Monday, reaching $5.27. The company's stock had a trading volume of 5,449,254 shares, compared to its average volume of 10,735,299. The company's 50-day moving average is $7.44 and its 200-day moving average is $7.01. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.20 and a 52 week high of $12.36. The firm has a market cap of $2.12 billion, a PE ratio of -3.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the previous year, the company earned ($0.42) earnings per share. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% compared to the same quarter last year. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have recently commented on RXRX shares. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $8.25.
View Our Latest Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Profile
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
